Cotinine (COT) Rapid Test

Cotinine, often shown as COT on drug testing panels, is the primary metabolite formed when the body breaks down nicotine. Nicotine may come from cigarettes, cigars, chewing tobacco, e-cigarettes, nicotine patches, gums, lozenges, or second-hand smoke exposure. Because cotinine remains in the body longer than nicotine, the Cotinine COT rapid test is commonly used for tobacco-use verification, smoking cessation monitoring, insurance health screening, workplace compliance, and nicotine exposure assessment.

• The COT urine rapid test checks for the presence of cotinine in human urine. A urine sample is applied to the rapid test device, and the result is interpreted according to the manufacturer’s instruction leaflet.
• The 200ng/ml cut-off means the test is designed to detect cotinine at or above the specified screening level.
• This Cotinine rapid test 200ng/ml is a preliminary screening tool. If results are used for employment, insurance, legal, clinical, or institutional decisions, confirmatory testing may be required through advanced laboratory methods, depending on local rules and testing policy.

• Urine is commonly used for cotinine testing because it is non-invasive, easy to collect, and suitable for rapid screening.
• A COT rapid test urine kit is especially useful when organizations need a practical screening method for recent nicotine exposure.
• It can support high-volume testing programs and helps reduce waiting time compared with more complex laboratory-based workflows.

The LARKSOIS Pharma Cotinine COT Rapid Test 200ng/ml may be used in professional diagnostic and institutional screening environments.

Applications

• Smoking cessation monitoring programs
• Tobacco and nicotine exposure screening
• Workplace and occupational health testing
• Insurance medical evaluation support
• Clinical and diagnostic laboratory testing
• Rehabilitation and wellness programs
• Public health and epidemiological screening
• Pre-surgical or treatment compliance programs, where applicable

Instructions

• Urine-based rapid test format
• 200ng/ml cut-off for cotinine screening
• Easy-to-use qualitative result
• Suitable for professional testing environments
• Helpful for tobacco and nicotine exposure monitoring
• Supports workplace, clinical, and wellness screening
• International B2B product suitability
• Backed by LARKSOIS Pharma’s diagnostic product focus

• Cotinine detection depends on many factors, including nicotine exposure level, frequency of use, metabolism, hydration, body condition, passive smoke exposure, and test sensitivity.
• Cotinine may remain detectable for several days depending on the exposure pattern and testing method.
• For this reason, a COT test result should be interpreted carefully and should not be used alone without considering testing policy, patient history, exposure type, and confirmatory requirements.

The Cotinine (COT) Rapid Test uses a rapid urine screening method for qualitative detection of cotinine. It is designed to provide a preliminary screening result at the stated 200ng/ml cut-off.

Benefits

• Urine-based rapid screening format
• 200ng/ml cotinine cut-off
• Designed for COT nicotine exposure screening
• Suitable for professional diagnostic use
• Supports fast preliminary results
• Useful for workplace, insurance, clinical, and wellness screening
• Applicable for laboratories, clinics, and institutions
• Supports international nicotine exposure screening requirements

The Cotinine (COT) Rapid Test is designed for urine specimens. Urine is widely used for cotinine screening because it is practical, non-invasive, and suitable for professional nicotine exposure monitoring workflows.

Guidance

• Use urine specimens only
• Use clean sample collection procedures
• Follow the product insert carefully
• Treat all urine samples as potentially biohazardous
• Interpret results within the stated reading window
• Use confirmatory testing where required by clinical, insurance, workplace, or institutional policy

Note

A rapid screening result should be considered preliminary unless confirmed by a validated laboratory method where required.

The Cotinine (COT) Rapid Test by LARKSOIS Pharma has a stated cut-off of 200ng/ml. This means the test is designed to screen for cotinine in urine at or above the validated threshold. LARKSOIS Pharma should mention the exact performance details according to the final product insert, technical file, and regulatory documentation.

Steps

• Bring the test device and urine specimen to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect urine using a clean sample collection procedure
• Apply the urine specimen according to the product insert
• Wait for the test reaction to complete within the instructed time
• Read the result within the approved interpretation window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Cotinine (COT) Rapid Test.

Positive

A positive result suggests that cotinine may be present in the urine specimen at or above the stated cut-off. Positive results are preliminary unless confirmed by an appropriate laboratory method.

Negative

A negative result suggests that cotinine was not detected or was below the test cut-off at the time of testing. A negative result does not replace clinical or professional judgment.

Invalid

If the control indicator does not appear, the result is invalid. The test should be repeated with a new device and fresh urine specimen according to the product insert.

Instructions

• Store in a cool and dry place
• Keep away from direct sunlight
• Do not freeze the test kit
• Keep the pouch sealed until use
• Avoid moisture exposure
• Use before the expiry date
• Keep away from children and unauthorized handling

Instructions

• For professional screening use only
• Use urine specimen only
• Do not use expired, opened, or damaged kits
• Read the instruction leaflet before testing
• Follow local testing rules and laboratory standards
• Do not interpret results after the recommended reading time
• Nicotine replacement products may affect cotinine results
• Second-hand smoke exposure may also influence results
• Positive or disputed results may require confirmatory laboratory testing

LARKSOIS Pharma supplies diagnostic and pharmaceutical products for international healthcare markets. The Cotinine COT Rapid Test 200ng/ml is designed for buyers who need reliable, urine-based rapid screening products for nicotine and tobacco exposure monitoring.

Advantages

• Urine-based nicotine exposure screening
• 200ng/ml cotinine cut-off
• Rapid qualitative result format
• Suitable for professional diagnostic programs
• Useful for workplace, insurance, wellness, and institutional testing
• Supports preliminary cotinine screening workflows
• International product positioning under LARKSOIS Pharma